Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) Assets Average (2024 - 2025)

Prelude Therapeutics' Assets Average history spans 2 years, with the latest figure at $118.0 million for Q4 2025.

  • For Q4 2025, Assets Average fell 36.67% year-over-year to $118.0 million; the TTM value through Dec 2025 reached $118.0 million, down 36.67%, while the annual FY2025 figure was $158.4 million, N/A changed from the prior year.
  • Assets Average for Q4 2025 was $118.0 million at Prelude Therapeutics, up from $104.8 million in the prior quarter.
  • Across five years, Assets Average topped out at $235.7 million in Q2 2024 and bottomed at $104.8 million in Q3 2025.